<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490047</url>
  </required_header>
  <id_info>
    <org_study_id>LUD2011-001</org_study_id>
    <nct_id>NCT01490047</nct_id>
  </id_info>
  <brief_title>Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas</brief_title>
  <official_title>Phase I Trial of Intravenous Recombinant Human TNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig Institute for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig Institute for Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of recombinant human
      tumor necrosis factor-α (rhTNF-α) when given as a single dose intravenously and in
      combination with liposomal doxorubicin in human subjects
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2013</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of a single dose of intravenous recombinant human tumor necrosis factor-α plus liposomal doxorubicin</measure>
    <time_frame>Up to 22 days</time_frame>
    <description>MTD is the dose level below the one that produces 2 or more Dose-Limiting Toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) of a single dose of intravenous recombinant human tumor necrosis factor-α plus liposomal doxorubicin</measure>
    <time_frame>up to 22 days</time_frame>
    <description>Toxicity Criteria will be those listed in NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Any grade 3 cytokine release syndrome/acute infusion reaction or allergic and toxicity Grade 3 and above will be considered a DLT except:
Grade 3 toxicities that recover to grade 1 or less within 48 hours after standard supportive treatment.
Grade 4 neutropenia that recovers within 14 days.
Grade 4 thrombocytopenia that recovers within 14 days.
Grade 4 anemia that recovers within 14 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall tumor response using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caelyx/doxorubicin plasma levels</measure>
    <time_frame>0, 24, 48 and 192 hours post‐dose</time_frame>
    <description>Caelyx/doxorubicin plasma levels will be measured at 0, 24, 48 and 192 hours post‐dose by fluorimetry (excitation at 470nm, emission 590 nm) after liposomes have been disrupted in 70% ethanol, 0.3 N HCl</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Lymphomas</condition>
  <arm_group>
    <arm_group_label>rhTNF-α 25 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: rhTNF-α 25 µg/m² + Caelyx 40 mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhTNF-α 50 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3: rhTNF-α 50 µg/m² + Caelyx 40 mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhTNF-α 100 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4: rhTNF-α 100 µg/m² + Caelyx 40 mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhTNF-α 150 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5: rhTNF-α 150 µg/m² + Caelyx 40 mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhTNF-α 200 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 6: rhTNF-α 200 µg/m² + Caelyx 40 mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhTNF-α 250 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 7: rhTNF-α 250 µg/m² + Caelyx 40 mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhTNF-α 25 µg/m² + Caelyx 30 mg/m²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 rhTNF-α 25 µg/m² + Caelyx 30 mg/m²</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human TNF-α</intervention_name>
    <description>Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.</description>
    <arm_group_label>rhTNF-α 25 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 50 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 100 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 150 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 200 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 250 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 25 µg/m² + Caelyx 30 mg/m²</arm_group_label>
    <other_name>Beromun</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal doxorubicin</intervention_name>
    <description>Infusion over 60 minutes</description>
    <arm_group_label>rhTNF-α 25 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 50 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 100 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 150 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 200 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 25 µg/m² + Caelyx 30 mg/m²</arm_group_label>
    <other_name>Caelyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caelyx</intervention_name>
    <description>Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.</description>
    <arm_group_label>rhTNF-α 25 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 50 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 100 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 150 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 200 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 250 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 25 µg/m² + Caelyx 30 mg/m²</arm_group_label>
    <other_name>liposomal doxorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human TNF-α</intervention_name>
    <description>Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.</description>
    <arm_group_label>rhTNF-α 25 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 50 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 100 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 150 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 200 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 250 µg/m² + Caelyx 40 mg/m²</arm_group_label>
    <arm_group_label>rhTNF-α 25 µg/m² + Caelyx 30 mg/m²</arm_group_label>
    <other_name>Beromun</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must have a diagnosed solid tumor malignancy or lymphoma indicated for Caelyx
             treatment.

          -  Patient is refractory to all lines of standard therapy including biologics, chemo or
             other therapies, or at least one line of therapy in those patients for whom no
             standard treatment exists.

          -  Patient has measurable disease (defined as at least one lesion whose longest diameter
             can be accurately measured as &gt;1 cm).

          -  At least 2 weeks has elapsed since the completion of the last cycle of chemotherapy
             and/or major surgery and the patient is fully recovered from this previous therapy or
             surgery and any post-surgical complications.

          -  The patient has a normal cardiac ejection fraction on MUGA or Echocardiogram.

          -  ECOG performance status of 2 or less.

          -  Patient is at least 18 years of age.

          -  Patient is capable of giving informed consent.

          -  Patient of childbearing potential is using adequate birth control measures (e.g.,
             abstinence, barrier method with spermicide; intrauterine device, implantable or
             injectable contraceptives or surgical sterilization) for the duration of the study and
             will continue to use such precautions for 12 months after receiving treatment.

        Exclusion Criteria:

          -  Positive pregnancy test or known pregnancy.

          -  Participation in any other clinical trial

          -  Known hypersensitivity to the active substance or to any of the excipients (Albumin).

          -  Patients exposed to greater than 450 mg/m2 of doxorubicin or Caelyx.

          -  Patient has a creatinine &gt; 1.5 x the upper limit of normal, chronic renal failure
             requiring hemodialysis or peritoneal dialysis.

          -  Platelet count equal to or less than 50,000/mm3, Hemoglobin less than 9.0 g/dL, or an
             ANC less than 1,000 /mm3.

          -  Patient has a Sa02 of less than 93% on room air.

          -  Patient with detectable ascites or portosystemic hypertension or cirrhosis.

          -  Patient with bilirubin &gt; 2.0, AST or ALT above 2.5X the upper limit of normal, an
             alkaline phosphatase above 2.5X the upper limit of normal.

          -  Hypercalcaemia &gt; 12 mg/dl (2.99 mmol/l).

          -  Patients with contraindications to the use of vasopressor substances.

          -  Patient has presence of a transplanted solid organ (with the exception of a corneal
             transplant &gt; 3 months prior to screening) or bone marrow transplant.

          -  Patient has a history of a significant medical illness deemed by the principal
             investigator or sub-investigators as unsuitable for the trial, for example:
             Significant cardiovascular disease, e.g. congestive heart failure (New York Heart
             Association Class II, III or IV), severe angina pectoris, cardiac arrhythmias,
             myocardial infarction within a 3 month period prior to treatment, venous thrombosis,
             occlusive peripheral arterial disease, recent pulmonary embolism. Severe pulmonary
             dysfunction. A recent history of, or active peptic ulcer. Severe ascites. Known
             hypotension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elke Jäger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Nordwest, Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2011</study_first_posted>
  <last_update_submitted>June 15, 2015</last_update_submitted>
  <last_update_submitted_qc>June 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

